Medexus Pharmaceuticals (MDP) Stock Price, News & Analysis

Company Overview

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Treosulfan, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; Tricovel tablets with Biogenina to reduce hair shedding due to Telogen Eflluvium; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada.

Key Stats

• Today's Range: C$2.61 to C$2.82
• 50-Day Range: C$1.96 to C$3.05
• 52-Week Range: C$1.47 to C$3.27
• Volume: 5,850 shs
• Average Volume: 40,298 shs
• Market Capitalization: C$69.17 million
• P/E Ratio: 56.40
• Dividend Yield: N/A
• Price Target: C$5.25
• Consensus Rating: Buy

MDP Stock Analysis - Frequently Asked Questions

How have MDP shares performed this year?

Medexus Pharmaceuticals' stock was trading at C$2.47 at the beginning of the year. Since then, MDP shares have increased by 14.2% and is now trading at C$2.82.
View the best growth stocks for 2024 here.

How do I buy shares of Medexus Pharmaceuticals?

Shares of MDP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of Medexus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Medexus Pharmaceuticals investors own include AutoZone (AZO), Cisco Systems (CSCO), Facedrive (FDVRF), Intel (INTC), kneat.com (KSI), NIO (NIO) and Nanotech Security (NTS).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: TSE:MDP
• CUSIP: N/A
• CIK: N/A
• Web: www.medexus.com
• Phone: 877-633-3987
• Fax: N/A
• Employees: 98
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: C$5.25
• High Stock Price Target: C$8.25
• Low Stock Price Target: C$3.50
• Potential Upside/Downside: +86.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): C$0.05
• Trailing P/E Ratio: 56.40
• Forward P/E Ratio: 17.27
• P/E Growth: N/A
• Net Income: C$1.09 million
• Net Margins: 1.00%
• Pretax Margin: N/A
• Return on Equity: 3.95%
• Return on Assets: 4.89%

Debt

• Debt-to-Equity Ratio: 143.72
• Current Ratio: 1.11
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: C$108.78 million
• Price / Sales: 0.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: C$1.33 per share
• Price / Book: 2.12

Miscellaneous

• Outstanding Shares: 24,530,000
• Free Float: N/A
• Market Cap: C$69.17 million
• Optionable: Not Optionable
• Beta: 1.96